Claims

1. A pharmaceutical composition consisting essentially of:
   (a) nebivolol and/or a pharmaceutically acceptable salt thereof, and
   (b) a semifluorinated alkane;

   wherein the nebivolol and/or a pharmaceutically acceptable salt thereof is suspended in the semifluorinated alkane, and wherein at least 90% of the suspended particles of nebivolol and/or a pharmaceutically acceptable salt thereof have a size of not more than about 15 μm.

2. The pharmaceutical composition according to claim 1, wherein the semifluorinated alkane is a semifluorinated alkane of the formula (II)

   $$CF_3(CF_2)_n(CH_2)_mCH_3 \quad (II),$$

   wherein n is an integer from 2 to 10 and m is an integer from 2 to 10;

   or

   wherein n is an integer from 3 to 5 and m is an integer from 4 to 7.

3. The pharmaceutical composition of claim 1 or claim 2, wherein the semifluorinated alkane is selected from the group consisting of 1-perfluorobutyl-pentane ($CF_3(CF_2)_3(CH_2)_4CH_3$; F4H5) and 1-perfluorohexyl-octane ($CF_3(CF_2)_5(CH_2)_7CH_3$, F6H8).

4. The pharmaceutical composition of any one of the preceding claims, wherein the pharmaceutically acceptable salt of nebivolol is suspended in the semifluorinated alkane.

5. The pharmaceutical composition of any one of the preceding claims, wherein the nebivolol and/or a pharmaceutically acceptable salt thereof is suspended in the semifluorinated alkane at a concentration of from 0.3 to 1.5 % (w/v).

6. The pharmaceutical composition of any one of the preceding claims, wherein the nebivolol and/or a pharmaceutically acceptable salt thereof is suspended in the semifluorinated alkane at a concentration of from 0.45 to 1.0 % (w/v).

7. The pharmaceutical composition of any one of the preceding claims, wherein the nebivolol is in the form of nebivolol hydrochloride.

8. The pharmaceutical composition of any one of claims 4 to 7, wherein at least about 90% of the suspended particles of the nebivolol and/or a pharmaceutically acceptable salt thereof have a size of not more than about 10 μm.

9. The pharmaceutical composition of any one of the preceding claims for use as a medicament.

10. The pharmaceutical composition for use according to claim 9, in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith.

11. The pharmaceutical composition for use according to claim 10, wherein the composition is administered to an eye of a subject once daily.

12. The pharmaceutical composition according to claim 11, wherein the composition is administered to the eye of a subject in a single dose from about 45 to about 120μg.

13. The pharmaceutical composition for the use according to any one of claims 10 to 12, wherein the pharmaceutical composition is administered in a dose volume per eye of 8 to 15 μl.

14. The pharmaceutical composition for the use according to any one of claims 10 to 13 , wherein the pharmaceutical composition is administered in a dose volume per eye of 10 to 12 μl and wherein the composition comprises the nebivolol and/or a pharmaceutically acceptable salt thereof suspended in the semifluorinated alkane in a concentration of at least 0.3% (w/v).

15. The pharmaceutical composition for the use according to any one of claims 11 to 14, wherein the pharmaceutical composition comprises nebivolol and/or a pharmaceutically acceptable salt thereof suspended in the semifluorinated alkane in a concentration of from 0.45 to 1.0 % (w/v).

16. The pharmaceutical composition of any one of the preceding claims, wherein the pharmaceutical composition is essentially free of water.

17. The pharmaceutical composition of any one of the preceding claims, wherein the pharmaceutical composition is preservative-free and microbiologically stable.

18. The pharmaceutical composition of claim 17, provided in a multi-dose or single dose format.

19. The pharmaceutical composition of any one of the preceding claims, wherein the composition consists essentially of nebivolol hydrochloride and a semifluorinated alkane selected from F4H5, F4H6, F4H7, F4H8, F5H5, F5H6, F5H7, F5H8, F6H5, F6H6, F6H7, F6H8, F8H8, and F6H10.

20. The pharmaceutical composition of claim 19, wherein the pharmaceutical composition consists essentially of nebivolol hydrochloride and a semifluorinated alkane selected from 1-perfluorobutyl-pentane (F4H5) and 1-perfluorohexyl-octane (F6H8).

21. The pharmaceutical composition of any one of the preceding claims, wherein the pharmaceutical composition is essentially free of water, preservative-free, and substantially free of surfactant.

22. Use of:

(a) nebivolol and/or a pharmaceutically acceptable salt thereof, and
(b) a semifluorinated alkane;

in the manufacture of a pharmaceutical composition for treating glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith.

23. A kit comprising the pharmaceutical composition according to any one of the claims 1 to 21 and a container for holding the pharmaceutical composition.